dr aubrey de grey chief science officer rejuvenation technology: applying regenerative medicine to...
TRANSCRIPT
![Page 1: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/1.jpg)
Dr Aubrey de GreyChief Science Officer
Rejuvenation technology: applying regenerative
medicine to aging
Aubrey D.N.J. de Grey, Ph.D.Chief Science Officer, SENS Foundation
![Page 2: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/2.jpg)
Dr Aubrey de GreyChief Science Officer
SENS Foundation
SENS Foundation is a US-registered charity that works to develop, promote
and enable widespread access to regenerative medicine solutions to the
disabilities and diseases of…
AGING
![Page 3: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/3.jpg)
Dr Aubrey de GreyChief Science Officer
Who dies of aging?
Death from aging is not only “natural causes”
It’s anything that mainly kills older people
About 150,000 people die per day worldwide
Two thirds of them die of aging: 100,000/day
In the USA, the proportion is over 90%
![Page 4: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/4.jpg)
Dr Aubrey de GreyChief Science Officer
Fun
Why are we doing this?
Not fun
![Page 5: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/5.jpg)
Dr Aubrey de GreyChief Science Officer
Repair versus retardation
Specifics: the seven types of damage
Intracellular junk/medical bioremediation
Longevity escape velocity: the concept
Some evidence that LEV is realistic
How you can make a difference
Structure of this talk
![Page 6: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/6.jpg)
Dr Aubrey de GreyChief Science Officer
Repair versus retardation
Specifics: the seven types of damage
Intracellular junk/medical bioremediation
Longevity escape velocity: the concept
Some evidence that LEV is realistic
How you can make a difference
Structure of this talk
![Page 7: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/7.jpg)
Dr Aubrey de GreyChief Science Officer
- Regenerative medicine?
- Aging?
What is…
![Page 8: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/8.jpg)
Dr Aubrey de GreyChief Science Officer
Any intervention that seeks to restore a tissue/organ to its state before it suffered
damage.
What is regen med?
![Page 9: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/9.jpg)
Dr Aubrey de GreyChief Science Officer
Metabolism
ongoingly causes “damage”.
Damage
eventually causes pathology.
What is aging?
![Page 10: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/10.jpg)
Dr Aubrey de GreyChief Science Officer
Pathology
Options for intervention
Gerontology Geriatrics
Metabolism Damage
![Page 11: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/11.jpg)
Dr Aubrey de GreyChief Science Officer
Problem 1: this is pathologyCancer
Heart Disease
Diabetes
Incontinence
Osteoporosis
Macular Degeneration
Stroke
Sarcopenia
Osteoarthritis
Hormonal Imbalance
Kidney Failure
Parkinson’s
Pneumonia
Emphysema
Sex Drive
…and LOTS more
Alzheimer’s
![Page 12: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/12.jpg)
Dr Aubrey de GreyChief Science Officer
Problem 2: this is metabolism
![Page 13: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/13.jpg)
Dr Aubrey de GreyChief Science Officer
If VW Bugs were built to last
![Page 14: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/14.jpg)
Dr Aubrey de GreyChief Science Officer
Maintained to last
![Page 15: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/15.jpg)
Dr Aubrey de GreyChief Science Officer
Pathology
Options for interventionGerontology Geriatrics
Metabolism Damage
Maintenance
Claim: unlike the others, the maintenance approach may achieve a big extension of human healthy lifespan quite soon.
![Page 16: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/16.jpg)
Dr Aubrey de GreyChief Science Officer
Repair versus retardation
Specifics: the seven types of damage
Intracellular junk/medical bioremediation
Longevity escape velocity: the concept
Some evidence that LEV is realistic
How you can make a difference
Structure of this talk
![Page 17: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/17.jpg)
Dr Aubrey de GreyChief Science Officer
It targets initially inert intermediates (“damage”).
Reasons for the maintenance approach
![Page 18: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/18.jpg)
Dr Aubrey de GreyChief Science Officer
It targets initially inert intermediates (“damage”).
Reasons for the maintenance approach
Damage is simpler than metabolism or pathology.
![Page 19: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/19.jpg)
Dr Aubrey de GreyChief Science Officer
This is the damage
No new type of damage confirmed since 1982.
Seven Deadly Things
1. Junk - Inside Cells
2. Junk - Outside Cells
3. Cells - Too Few
4. Cells - Too Many
5. Mutations - Chromosomes
6. Mutations - Mitochondria
7. Protein Crosslinks
![Page 20: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/20.jpg)
Dr Aubrey de GreyChief Science Officer
Giving the middle-aged 30 years of extra healthy life:
Robust Human Rejuvenation
Damage rising with age It or its effects reversible by
Cell loss, cell atrophy Cell therapy, mainly
Extracellular junk Phagocytosis by immune stimulation
Extracellular crosslinks AGE-breaking molecules/enzymes
Death-resistant cells Suicide genes, immune stimulation
Mitochondrial mutations Allotopic expression of 13 proteins
Intracellular junk Transgenic microbial hydrolasesNuclear [epi]mutations (only cancer matters)
Telomerase/ALT gene deletion plus periodic stem cell reseeding
![Page 21: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/21.jpg)
Dr Aubrey de GreyChief Science Officer
Repair versus retardation
Specifics: the seven types of damage
Intracellular junk/medical bioremediation
Longevity escape velocity: the concept
Some evidence that LEV is realistic
How you can make a difference
Structure of this talk
![Page 22: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/22.jpg)
Dr Aubrey de GreyChief Science Officer
Giving the middle-aged 30 years of extra healthy life:
Robust Human Rejuvenation
Damage rising with age It or its effects reversible by
Cell loss, cell atrophy Cell therapy, mainly
Extracellular junk Phagocytosis by immune stimulation
Extracellular crosslinks AGE-breaking molecules/enzymes
Death-resistant cells Suicide genes, immune stimulation
Mitochondrial mutations Allotopic expression of 13 proteins
Intracellular junk Transgenic microbial hydrolasesNuclear [epi]mutations (only cancer matters)
Telomerase/ALT gene deletion plus periodic stem cell reseeding
![Page 23: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/23.jpg)
Dr Aubrey de GreyChief Science Officer
Intracellular junk in Alzheimer’s
IEM: Calnexin
Dystrophic Neurites IEM: Cat D
![Page 24: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/24.jpg)
Dr Aubrey de GreyChief Science Officer
Endothelial Cells
Lipid-engorged Lysosome
Foam Cell
Intracellular junk in the artery
![Page 25: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/25.jpg)
Dr Aubrey de GreyChief Science Officer
Microbes, like all life, need an ecological niche.
Some get it by brawn (growing very fast)…
…some by brain (living off material that others can't).
Any abundant, energy-rich organic material that is hard to degrade thus provides selective pressure to evolve the machinery to degrade it.
That selective pressure works. Even TNT, PCBs…
Bioremediation: the concept
![Page 26: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/26.jpg)
Dr Aubrey de GreyChief Science Officer
Graveyards
are abundant in human remains,
accumulate bones (which are not energy-rich),
do not accumulate oxysterols, tau etc.,
so, should harbour microbes that degrade them…
…whose catabolic enzymes could be therapeutic
Xenocatabolism: the concept
![Page 27: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/27.jpg)
Dr Aubrey de GreyChief Science Officer
Environmental decontamination in vivo
![Page 28: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/28.jpg)
Dr Aubrey de GreyChief Science Officer
7-ketocholesterol degradationa promising start
Biodegradation 2008; 19(6):807-813
7KC over time in enrichment cultures
days
![Page 29: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/29.jpg)
Dr Aubrey de GreyChief Science Officer
Dione metabolite ?M = 398, M13C = 399
O O
OH
O OOH O
Stable isotope labelling and LC/MS reveal 7-ketocholesterol metabolites in the culture supernatant
Culture growing on7-ketocholesterol
Culture growing on13C-labeled 7-ketocholesterol
7-ketocholesterolM = 400, M13C = 401
Hydroxylated dione ?M = 414, M13C = 415
![Page 30: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/30.jpg)
Dr Aubrey de GreyChief Science Officer
1) Isolate competent strains; select by starvation.
2) Identify the enzymes (mutagenesis, chemistry, genomics).
3) Make lysosome-targeted transgenes; assay cell toxicity.
4) Assay competence in vitro (more mutagenesis/selection).
5) Construct transgenic mice; assay toxicity in vivo.
6) Assay competence in disease mouse models.
7) Test in humans as for lysosomal storage diseases.
Steps to biomedical application
![Page 31: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/31.jpg)
Dr Aubrey de GreyChief Science Officer
Repair versus retardation
Specifics: the seven types of damage
Intracellular junk/medical bioremediation
Longevity escape velocity: the concept
Some evidence that LEV is realistic
How you can make a difference
Structure of this talk
![Page 32: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/32.jpg)
Dr Aubrey de GreyChief Science Officer
Giving the middle-aged 30 years of extra healthy life:
Robust Human Rejuvenation
Damage rising with age It or its effects reversible by
Cell loss, cell atrophy Cell therapy, mainly
Extracellular junk Phagocytosis by immune stimulation
Extracellular crosslinks AGE-breaking molecules/enzymes
Death-resistant cells Suicide genes, immune stimulation
Mitochondrial mutations Allotopic expression of 13 proteins
Intracellular junk Transgenic microbial hydrolasesNuclear [epi]mutations (only cancer matters)
Telomerase/ALT gene deletion plus periodic stem cell reseeding
![Page 33: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/33.jpg)
Dr Aubrey de GreyChief Science Officer
Only 30 years? Hardly “defeating aging”!
Damage rising with age It or its effects reversible by
Cell loss, cell atrophy Cell therapy, mainly
Extracellular junk Phagocytosis by immune stimulation
Extracellular crosslinks AGE-breaking molecules/enzymes
Death-resistant cells Suicide genes, immune stimulation
Mitochondrial mutations Allotopic expression of 13 proteins
Intracellular junk Transgenic microbial hydrolasesNuclear [epi]mutations (only cancer matters)
Telomerase/ALT gene deletion plus periodic stem cell reseeding
![Page 34: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/34.jpg)
Dr Aubrey de GreyChief Science Officer
It targets initially inert intermediates (“damage”).
Reasons for the maintenance approach
Damage is simpler than metabolism or pathology.
Repairing damage buys time.
![Page 35: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/35.jpg)
Dr Aubrey de GreyChief Science Officer
Age
Res
erve
00
max
frail
Progress avoids diminishing returns
Fixing half the damage, then 3/4, then 7/8, …
(a) outpaces the so-far-unfixable damage, and
(b) maintains healthspan indefinitely.
![Page 36: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/36.jpg)
Dr Aubrey de GreyChief Science Officer
The rate at which rejuvenation therapies must improve (following the achievement of RHR) in order to outpace the accumulation of
so-far-irreparable damage.
Longevity escape velocity (LEV)
![Page 37: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/37.jpg)
Dr Aubrey de GreyChief Science Officer
Repair versus retardation
Specifics: the seven types of damage
Intracellular junk/medical bioremediation
Longevity escape velocity: the concept
Some evidence that LEV is realistic
How you can make a difference
Structure of this talk
![Page 38: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/38.jpg)
Dr Aubrey de GreyChief Science Officer
1903
What rate of progressis realistic?
196919491927
![Page 39: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/39.jpg)
Dr Aubrey de GreyChief Science Officer
Metabolism ongoingly causes “damage”
and
damage eventually causes pathology.
so…
Simulations of aging (and intervention) should simulate damage accumulation.
Simulating aging(Phoenix & de Grey, AGE 2007; 29:133)
![Page 40: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/40.jpg)
Dr Aubrey de GreyChief Science Officer
Results: LEV is very easyTherapies double efficacy only every 42 years.
0 150 200 300250 35010050 Age (years)
Pro
port
ion
dead
by
age
N
![Page 41: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/41.jpg)
Dr Aubrey de GreyChief Science Officer
Data
![Page 42: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/42.jpg)
Dr Aubrey de GreyChief Science Officer
The first 1000-year-old is probably less than
20 years younger thanthe first 150-year-old.
What this means
![Page 43: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/43.jpg)
Dr Aubrey de GreyChief Science Officer
Immortality is science fictionLEV ~= immortalitySENS implies LEV
SENS is science fiction
What it doesn’t mean
![Page 44: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/44.jpg)
Dr Aubrey de GreyChief Science Officer
First it’s scientifically absurd and secondly it’s scientifically irresponsible. Tom Kirkwood
Aubrey represents the paramilitary wing of gerontology. Richard Faragher
Resistance to debate on how to postpone aging is delaying progress and costing lives.
Aubrey de Grey
Irresponsible? An ongoing debate.
![Page 45: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/45.jpg)
Dr Aubrey de GreyChief Science Officer
Repair versus retardation
Specifics: the seven types of damage
Intracellular junk/medical bioremediation
Longevity escape velocity: the concept
Some evidence that LEV is realistic
How you can make a difference
Structure of this talk
![Page 46: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/46.jpg)
Dr Aubrey de GreyChief Science Officer
Learn more
Available at Amazon and all good book stores.
Paperback is cheaper, and has an extra chapter!
Visit us on the web athttp://www.sens.org/
Read the (semi-technical) book.
Drop us a line [email protected]
![Page 47: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/47.jpg)
Dr Aubrey de GreyChief Science Officer
Support SENS FoundationSENS Foundation works to develop, promote and enable widespread access to regenerative medicine solutions to the disabilities and diseases of aging.
To be successful in our mission we need your support.
Time - On our website you will find details of how your skills can be used to accelerate our progress, and help us to make these audacious ideas into a reality.
Money - You may also wish to make a donation. Any amount, no matter how small, helps to fund essential research, education and outreach initiatives.
![Page 48: Dr Aubrey de Grey Chief Science Officer Rejuvenation technology: applying regenerative medicine to aging Aubrey D.N.J. de Grey, Ph.D. Chief Science Officer,](https://reader035.vdocument.in/reader035/viewer/2022062417/551ba248550346167e8b5ae6/html5/thumbnails/48.jpg)
Dr Aubrey de GreyChief Science Officer
SENS FoundationSENS Foundation works to develop, promote and ensure widespread access to regenerative medicine solutions to the disabilities and diseases of aging.